These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28953944)

  • 1. Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates.
    Grimaldi G; Teva A; Dos-Santos CB; Santos FN; Pinto ID; Fux B; Leite GR; Falqueto A
    PLoS One; 2017; 12(9):e0185438. PubMed ID: 28953944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis.
    Fernandes CB; Junior JT; de Jesus C; Souza BM; Larangeira DF; Fraga DB; Tavares Veras PS; Barrouin-Melo SM
    Vaccine; 2014 Mar; 32(11):1287-95. PubMed ID: 24406392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil.
    Regina-Silva S; Feres AM; França-Silva JC; Dias ES; Michalsky ÉM; de Andrade HM; Coelho EA; Ribeiro GM; Fernandes AP; Machado-Coelho GL
    Vaccine; 2016 Apr; 34(19):2233-9. PubMed ID: 26997002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
    Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
    Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran.
    Daneshvar H; Namazi MJ; Kamiabi H; Burchmore R; Cleaveland S; Phillips S
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2757. PubMed ID: 24743691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sand fly synthetic sex-aggregation pheromone co-located with insecticide reduces the incidence of infection in the canine reservoir of visceral leishmaniasis: A stratified cluster randomised trial.
    Courtenay O; Dilger E; Calvo-Bado LA; Kravar-Garde L; Carter V; Bell MJ; Alves GB; Goncalves R; Makhdoomi MM; González MA; Nunes CM; Bray DP; Brazil RP; Hamilton JGC
    PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007767. PubMed ID: 31652261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplacental transmission of Leishmania infantum as a means for continued disease incidence in North America.
    Boggiatto PM; Gibson-Corley KN; Metz K; Gallup JM; Hostetter JM; Mullin K; Petersen CA
    PLoS Negl Trop Dis; 2011 Apr; 5(4):e1019. PubMed ID: 21532741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and factors associated with Leishmania infantum infection of dogs from an urban area of Brazil as identified by molecular methods.
    Coura-Vital W; Marques MJ; Veloso VM; Roatt BM; Aguiar-Soares RD; Reis LE; Braga SL; Morais MH; Reis AB; Carneiro M
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1291. PubMed ID: 21858243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of removing potentially infectious dogs on the numbers of canine Leishmania infantum infections in an endemic area with high transmission rates.
    Grimaldi G; Teva A; Santos CB; Ferreira AL; Falqueto A
    Am J Trop Med Hyg; 2012 Jun; 86(6):966-71. PubMed ID: 22665602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies elicited by the CaniLeish® vaccine: long-term clinical follow-up study of dogs in Spain.
    Montoya A; Checa R; Marino V; Gálvez R; Portero M; De Mari K; Navarro C; Miró G
    Parasitol Res; 2021 Apr; 120(4):1471-1479. PubMed ID: 33624147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis.
    Fernández Cotrina J; Iniesta V; Monroy I; Baz V; Hugnet C; Marañon F; Fabra M; Gómez-Nieto LC; Alonso C
    Vaccine; 2018 Apr; 36(15):1972-1982. PubMed ID: 29525281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological aspects of vector, parasite, and domestic reservoir in areas of recent transmission and no reported human cases of visceral leishmaniasis in Brazil.
    Lara-Silva Fde O; Michalsky ÉM; Fortes-Dias CL; Fiuza Vde O; Pessanha JE; Regina-Silva S; de Avelar DM; Silva MA; Lima AC; da Costa AJ; Machado-Coelho GL; Dias ES
    Acta Trop; 2015 Aug; 148():128-36. PubMed ID: 25882769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological diagnosis of canine leishmaniosis: comparison of three commercial ELISA tests (Leiscan, ID Screen and Leishmania 96), a rapid test (Speed Leish K) and an in-house IFAT.
    Solano-Gallego L; Villanueva-Saz S; Carbonell M; Trotta M; Furlanello T; Natale A
    Parasit Vectors; 2014 Mar; 7():111. PubMed ID: 24655335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area-A randomized controlled trial.
    Velez R; Domenech E; Rodríguez-Cortés A; Barrios D; Tebar S; Fernández-Arévalo A; Aguilar R; Dobaño C; Alberola J; Cairó J; Gállego M
    Acta Trop; 2020 May; 205():105387. PubMed ID: 32035053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
    Gravino AE
    Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons.
    Oliva G; Nieto J; Foglia Manzillo V; Cappiello S; Fiorentino E; Di Muccio T; Scalone A; Moreno J; Chicharro C; Carrillo E; Butaud T; Guegand L; Martin V; Cuisinier AM; McGahie D; Gueguen S; Cañavate C; Gradoni L
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3213. PubMed ID: 25299614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.